Asunaprevir - monotherapy

Drug Profile

Asunaprevir - monotherapy

Alternative Names: Asunaprevir (NS3 inhibitor) - BMS; ASV; BMS-650032; Sunvepra

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Bristol-Myers Squibb
  • Class Amides; Antivirals; Carbamates; Cyclopropanes; Isoquinolines; Pyrrolidines; Small molecules; Sulfonamides
  • Mechanism of Action Hepatitis C virus NS3 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Hepatitis C

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 27 Apr 2013 Bristol-Myers Squibb completes a phase II trial in Hepatitis C (combination therapy) in USA, European Union and Argentina (NCT01030432)
  • 28 Feb 2013 Bristol-Myers Squibb completes a phase I trial in Healthy volunteers and patients with kidney disease in USA (NCT01886599)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top